4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront

AstraZeneca (NYSE:AZN) began the week with an eye-popping deal for a potential new cancer drug in a relatively early stage of development. The big pharma will hand its favorite collaboration partner, Daiichi Sankyo (OTC:DSNK.Y), a whopping $1 billion upfront to develop and commercialize DS-1062, an experimental treatment for lung and breast cancer currently in phase 1 trials.